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Available online 30 December 2010The ubiquitin ligase SCFTrCP is required for internalisation of the growth hormone receptor (GHR) and
acts via a direct interactionwith the ubiquitin-dependent endocytosismotif. Details of how the ligase
communicates its information to the clathrin-mediated internalisation machinery are unknown. For
the EGF receptor, c-Cbl acts both at the cell surface and in endosomes.Wehypothesised that SCFTrCP is
required forGHRdegradation at both sites. Thiswas testedby truncatingGHRafter a di-leucine-based
internalisationmotif (GHR349). This receptor enters the cells via the adapter complex AP2.We show
that TrCP acts in an early stage of cargo selection: both TrCP silencing andmutation of the ubiquitin-
dependent endocytosis motif force the GHR to recycle between endosomes and the plasma
membrane, togetherwith the transferrin receptor. Depletion of Tsg101 (ESCRT-I) has the same effect,
while silencing of Hrs (ESCRT-0) prevents GH recycling. GH passes through late endosomal vesicles,
marked by Lamp1. Coexpressing GHR and EGFR demonstrates that both receptors use the same route
to the lysosomes. We show for the first time that SCFTrCP is involved in cargo-specific sorting at
endosomes and that Tsg101 rather than Hrs might direct the cargo into the ESCRT machinery.
© 2011 Elsevier Inc. Open access under the Elsevier OA license.Keywords:
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Cell surface signaling receptors use the common endocytic-
clathrin-driven route at the plasma membrane and the endosomal
sorting (ESCRT) machinery at the MVBs for their transport to
lysosomes. In addition, every signaling receptor requires specific
cargo selection at both sites. Here, a task for the ubiquitin system is
emerging. A limited set of ubiquitin ligases seems to be involved in
degradation of the receptor tyrosine kinases (RTK) as summarised
in [1]. For cytokine receptor degradation the SCFTrCP and the
Cullin5-based E3 ubiquitin SOCS ligase families play major roles
[2]. Again, different cytokine receptors are differently treated.
While the ubiquitin ligase SCFTrCP acts on the interferon-α receptor
1 (IFNAR1), the prolactin receptor (PRLR) as well as on the.
. Strous).
tor receptor; EpoR, erythr
VB, multivesicular body; P
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he Elsevier OA license.erythropoietin receptor (epoR) only after phosphorylation of a
canonical DSGxxS motif [3–5], the same E3 is required for GHR
degradation via theubiquitin dependent endocytosis (UbE)motif [6].
Endosomes receive cargo from the plasma membrane and
recycle it either back or select it for degradation in lysosomes. The
best-understood cargo-selection system on endosomes acts via
segregation in small intraluminal vesicles and is based on ubiquitin
moieties as selection markers. This machinery is composed of three
protein complexes (ESCRT-I, -II, -III), while Hrs-STAM (also
designated ESCRT-0) is considered to serve as a general entrance
to the system [7–10]. The tumor susceptibility gene 101 (Tsg101) in
ESCRT-I and EAP45 in ESCRT-II bind ubiquitinated cargo via their
UEVandGLUEdomains, respectively [11,12]. In vitro studies indicate
that ESCRT-I and -II are involved in deformation of the endosomalopoietin receptor; ESCRT, endosomal sorting complex required for
rlR, prolactin receptor; RTK, receptor tyrosine kinase; siRNA, small
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ubiquitinated cargo to the buds [13]. How the different ESCRT
complexes transfer their cargo is not fully understood.
Selection at MVBs for lysosomal degradation is crucial for
signaling receptors: it prevents endless recycling between endo-
somes and plasma membrane and allows precise control of
signalling complexes by limiting their lifetime. In general,
selection by the ESCRT system seems to depend on ubiquitinated
cargo with ubiquitin ligases as primary selectors. In only a few
cases such enzymes are implicated in the actual selection process.
Studies on the epidermal growth factor receptor (EGFR) and other
RTKs have identified c-Cbl in combination with Ubc4/5 [14]. In
yeast, careful studies by the group of Haguenauer–Tsapis have
identified Rsp5 as a major factor in cargo selection of several
transporters toward the vacuole [15]. Other ubiquitin ligases, such
as Nedd4 and Tal, have been implicated in ubiquitinating Hrs and
Tsg101, respectively, to downregulate these ESCRT components
[16,17]. Two deubiquitinating enzymes (USP8 and AMSH) have
been implicated in the regulation of EGFR degradation at the
ESCRT-0 level [18–20].
Cargo selection studies at theMVBs are difficult due to the fact that
most receptors require the ubiquitination machinery both at the cell
surface and at the MVBs. Interfering with the system inhibits
internalisation in the first place, seriously impeding study in the
second step. Also in our studies on GHR degradation we faced this
problem: GHR degradation depends on the UbE motif both for
internalisation and transport fromendosomes [21–23]. To circumvent
this problem, we have used a mutant GHR, truncated after a silent
di-leucine motif that becomes active after truncation. This truncated
GHR (GHR349) is very rapidly endocytosed, most likely via both the
ubiquitin-dependent endocytosis (UbE) motif/TrCP system and the
ubiquitin-independent di-leucine motif/adapter complex AP2.
However, to pass the endosomes and to progress to lysosomes GHR
trafficking depends on an active ubiquitin system. This feature allows
the GHR to bypass ubiquitination-dependent internalisation and
enables study of the sorting events at MVBs.
Most of our knowledge of the molecular mechanism of cargo
selection at the MVBs comes from studies on virus assembly and
degradation of receptor tyrosine kinases, notably the EGFR. As the
GHR is a prototype cytokine receptor and a key regulator in many
metabolic processes including Insulin-like Growth Factor-I, under-
standing its trafficking and degradation is important. For inter-
nalisation, GHR uses the SCFTrCP complex [6]. Previously, we showed
that theUbEmotif is also involved in targeting the truncatedGHR349
to lysosomes [23]. Here, we show that βTrCP (β-transducin repeats-
containing protein) acts in endosomes to direct GHR to lysosomes.
Consequently, ifβTrCP is absent or not able to associatewith theUbE
motif, GHR recycles back to the plasma membrane. There is a clear
difference in GH trafficking between gene silencing of the ubiquitin
receptors (Hrs in ESCRT- and Tsg101 in ESCRT-I). Finally, we show
thatGHRandEGFR, although selected bydifferent E3s, take the same
route via the ESCRT system into MVB vesicles to the lysosomes.Materials and methods
Materials, antibodies and DNA constructs
The rabbit wild type and mutant GHR cDNAs in pcDNA3 have
been described before [21]. Protein A-beads were from Repligen.Chemically synthesised siRNA duplexes were purchased from
Dharmacon, Thermo Fisher Scientific., Lafayette, CO. Antibody,
recognizing the cytoplasmic domain of the GHR, was raised
against amino acids 327–493 of the cytosolic tail of the GHR [24].
Polyclonal anti-βTrCP was described before [6], anti-Lamp1 was
from BD Pharmingen, antibody against the extracellular domain
of the GHR (Mab5) was from Santa Cruz Biotechnology, Inc.,
goat anti-mouse IgG Alexa488 from Molecular Probes, and goat
anti-rabbit IgG IRDye800 from Rockland Immunochemicals Inc,
Gilbertsville (PA). Alexa488-transferrin was from Molecular
Probes and EGF-Alexa fluor 488 streptavidin from Invitrogen.
Mouse monoclonal anti-FLAG (M2) was from Sigma. Immobi-
lised streptavidin was from Pierce, glutathione-sepharose from
Amersham Biosciences, and Ni-NTA agarose from Qiagen. Culture
media, fetal calf serum (FCS), L-glutamine, and antibiotics for
tissue culture were purchased from In VitroGen.
Cell culture
Hek293, U2OS, and rat ts41 cells were grown in DMEM (In
VitroGen) supplementedwith 10% FCS, 100 units/ml penicillin and
0.1 mg/ml streptomycin. Cells stably expressing the different GHR
proteins were grown in the same medium supplemented with
hygromycin (U2OS) or Geneticin (Hek293, ts41). All cells used
were grown at 37 °C with 5% CO2. Twice a week cells were washed
with phosphate buffered saline (PBS), detached from the flask
with Trypsin-EDTA (In VitroGen), diluted in fresh growth medium
and split into new culture flasks.
Transfections
Cells were transfected using Lipofectamin 2000 (In Vitrogen).
Seventy percent confluent cultures were transfected with
0.2–0.9 μg DNA in 12-well plates according to manufacturer's
protocol and used for western blot experiments and 125I-GH
binding experiments after 1–2 days. For fluorescence microscopy
cells were transfected with Fugene-6 (Roche, Applied Sciences).
To silence the expression of genes cells were transfected with
small interfering RNA (siRNA) using Lipofectamin 2000
according to the description of the manufacturer; 3 days after
transfection cells were used for western blot and 125I-GH binding
experiments. To silence TrCP the “combi probe” was used that
most effectively silenced both TrCP1 and 2 [6]. We routinely
tested the efficiency of the gene silencing. For all genes more
than 80% of the cells showed a clear phenotype. Control cells
were transfected with siRNA-GFP. To control the efficiency
of the gene silencing cells were either transiently transfected
with tagged versions of the genes or antibodies against the
endogenous proteins were used. Western blots were analysed
using an Odyssey infrared imaging system (Li-Cor Biosciences,
Lincoln, Nebraska).
125I-GH binding and internalisation
125I-Human GH was prepared using chloramine T [24]. For
internalisation experiments, cells, grown in poly-D-lysine coated
12-well plates, were washed with 1 ml MEM supplemented with
20 mM Hepes, pH 7.4 and 0.1% bovine serum albumin (BSA), and
incubated at 37 °C in a water bath for 1 h. After washing the cells
three times with ice-cold PBS-complete (PBS-c: PBS with 0.135 g/l
Fig. 1 – TrCP stabilises GHR349, does not affect its internalisation.
A. Schematic representation of the GHRs used in this study. The
wild type receptor (620 amino acids) contains the UbEmotif and
a silent di-leucine motif (DTDRLL) that can bind to the α-σ2
hemicomplex of the AP adapter [54]. The dileucine motif
becomes active in the GHR, truncated at amino acid 349. In
GHR349(F327A), the UbE motif was mutated to prevent TrCP
binding [6]. B. Hek293, stably expressing GHRs as indicated, were
treated with siRNAs to silence GFP (control), TrCP, and clathrin
heavy chain for 3 days, and incubated with 125I-GH. Specific
internalised 125I-GH was expressed as a percentage of total
radioactivity at 10 min. C. Western blot of GHR349, TrCP, and
actin in cell lysates after silencing of TrCP as compared to control
siRNA (GFP). The double band below GHR represents the GHR
species in the ER. All data in this figure are representative of three
independent experiments.
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Hepes/0.1% BSA) was added to the cells. 125I-GH was bound for 2 h
on ice. Unbound 125I-GH was aspirated and the cells were washed
three times with PBS-c. To measure uptake rate cells were
incubated 10 min at 37 °C in MEM/Hepes/0.1% BSA; to measure
GH degradation incubation was for 1 hour. Membrane associated
125I-GH was removed by treating the cells twice with 750 μl acid
wash (0.15 M NaCl, 50 mM glycine, 0.1% BSA, pH 2.5) for 5 min on
ice. Acid wash was collected in counting tubes and radioactivity
was measured using a LKB gamma counter. Cells were solubilised
overnight in 1 N NaOH. Internalised 125I-GH was determined by
measuring the radioactivity in the collected NaOH. Unspecific
counts were determined by incubating the cells with 125I-GH
together with excess unlabelled GH (9 μg/ml). Internalisation is
expressed as a percentage of the total specific radioactivity after
10 min at 37 °C.
Proteinase K treatment of cells
To degrade the extracellular domain of the GHR cells were grown
in 6 cm plates, washed once with ice-cold PBS-c and were treated
with proteinase K (0.7 mL, 0.5 mg/mL) in PBS/1 mM EDTA for
30 min on ice and transferred to tubes. The digestion was
terminated with 0.7 mL PBS with 2 mM phenylmethylsulfonyl
fluoride (PMSF) and the detached cells were centrifuged for 5 min
at 300g at 4 °C, washed three times with PBS containing 1 mM
PMSF and lysed in 300 μL lysis buffer. The lysate was centrifuged
for 5 min at 14,000g at 4 °C. 30 μL of sample was boiled with 10 μL
4 times sample buffer with 80 mM dithiothreitol.
Immune fluorescence microscopy
Cy3-GH was prepared using a Fluorolink-Cy3 label kit according
to the supplier's instructions (Amersham Biosciences). Trans-
fected cells, grown on coverslips, were incubated with Cy3-GH
(1 μg/ml), Alexa488-labelled transferrin (25 μg/ml), or biotin-
EGF Alexafluor 488 streptavidin (100 ng/mL). Cells were washed
with PBS to remove unbound label and fixed for 2 h in 3%
paraformaldehyde in phosphate buffer, pH 7.4. After fixation, the
cells were permeabilised in 0.2% Triton for 5 min and the cover
slips were incubated with anti-Lamp1 and fluorescently labelled
secondary antibodies. The cover slips were embedded in Mowiol,
and visualisation was performed using a Leica TCS 4D system.
Subcellular colocalisation was analysed under ImageJ using a
JACoP plug-in [25].
Lysis and immunoprecipitations
For immunoprecipitations, the cells were lysed in 20 mM Tris
pH 8.0, 150 mM NaCl, 0.5% NP40, 1 mM PMSF, 10 μg/ml
aprotinin, and 10 μg/ml leupeptin. Cell lysates were centrifuged
to pellet the nuclei and the supernatants were used to pull-
down the GHR using biotinylated GH and streptavidin beads [6],
and associated proteins were analysed by reducing SDS-PAGE
and transferred to Immobilon-FL polyvinylidenedifluoride
membrane (Millipore). Blots were immunostained with the
indicated primary antibodies followed by Alexa Fluor 680, IRDye
800 conjugated anti-mouse or anti-rabbit antibodies. Detection
was performed with an Odyssey system (Li-Cor Biosciences,
Lincoln, Nebraska).Results
TrCP gene silencing interferes with GHR degradation after
internalisation
The SCFTrCP is involved in GHR internalisation via clathrin-coated
pits. This mechanism uses a specific (UbE) motif in the GHR tail
that interacts directly via theWD40 domains without further post-
translational modifications [6]. Previously, we reported that this
motif is also involved in GHR transport through the endosomal
system [22,23]. To be able to study the details of this mechanism
we used a truncated GHR (GHR349) that carries a C-terminal
di-leucine motif (Fig. 1A). Via this motif GHR349 can internalise
without requiring the ubiquitination machinery. However, to
progress to lysosomes, GHR349 requires the machinery that acts
upon the UbE motif [22,23].
Fig. 2 – GH endocytosed via GHR349 accumulates in endosomes and at the cell surface in the absence of TrCP. A. Hek293 cells stably
expressing wtGHR or GHR349, treated with TrCP siRNA or control (GFP) for 3 days, were incubated with cy3-GH for 30 min, and fixed.
The localisation of cy3-GH was determined using confocal fluorescence microscopy. B. Ts-41 cells stably expressing GHR349 were
incubated at 30 °C or 39 °C overnight. Cy3GH was added for 30min, and the cells were fixed. Data are representative of 2 experiments.
C. Cells were treated with proteinase K on ice, lysed, and GHR was detected after electrophoresis on western blot using a monoclonal
anti-GHR antibody against the GH binding domain. m, mature GHR; p, precursor GHR present in the ER. D. Cells were incubated with
biotin-GH (1 μg/ml) for 60 min on ice, excess biotin-GH was removed, and the cells were lysed in triton-containing buffer. Part of the
lysates was used to detect endogenous TrCP and actin (lower panels). Cell surface GHRs were isolated using streptavidin-agarose beads
and detected on western blot. The absence of the ER species demonstrated the validity of the assay. Bar, 5 μm.
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asked whether the same mechanism is active at the endosomal
level. First, we compared internalisation of 125I-GH via wild type
GHR and GHR349. Fig. 1B shows that GH uptake via the GHR349 isFig. 3 – Effect of TrCP gene silencing on cy3-GH localisation. GHR34
30 min, then incubated with Alexa488-Tf without GH for 30 min, an
the cells were incubated with cy3-GH and then chased for 30 min w
and incubated with anti-Lamp1 and Alexa488-labelled anti-mouse
(cy3-GH) is in the lumen of a Lamp1-positive vesicle. The amount o
expressed as a coefficient of co-localisation (lower panel). Bar, 5 μtwice as rapid as via the wild type GHR (92% vs. 47% within
10 min). This is probably due to the high capacity of the
AP2-clathrin adapter system in Hek293 cells that acts via the
di-leucine motif of the GHR349. This was confirmed by measuring9-expressing Hek293 cells were incubated with cy3-GH for
d fixed with p-formaldehyde (A and B rows). In the C and D rows
ithout GH. After fixation the cells were treated with triton-X100
IgG. In C a typical endosome is depicted in which the cargo
f co-labelling was determined according to Manders and
m.
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was prevented (GHR349F327A): this receptor is almost as
effective as GHR349 in bringing 125I-GH inside the cells (82% of
control in 10 min). If the dileucine motif was mutated, the GHR349
requires again the ubiquitinationmachinery for endocytosis. Disabling
both motifs resulted in complete inhibition of internalisation [22]. To
investigate whether TrCP is involved in GH internalisation we used
cells that were treated with either siRNA for TrCP or clathrin heavy
chain. The cellular levels of clathrin and TrCP were less than 5% and
50%, respectively, compared to control siRNA (GFP). Under these
conditions, uptake of GH via thewild type GHR decreased ~50% (from
47% to 27%), while uptake via GHR349 and GHR349F327A hardly
dropped (92% to 84% and 82% to 80%, respectively). Silencing of
clathrin heavy chain (not shown) affected uptake via all three
receptors to the same extent (CHC, 29%, 38%, 39%), indicating that
both AP2 and TrCP adapter systems use clathrin-mediated internalisa-
tion. In Fig. 1Cwemeasured the levels of GHR349 inHek293 cells after
3 daysof TrCP silencing: a3-fold reductionof TrCPcauseda2- to3-fold
increase of GHR349 as compared to treatment with control siRNA.
GHR349(F327A) is a stable protein regardless of siRNA treatment [23].
As gene silencing of TrCP causes inhibition of GHR349 degrada-
tion without affecting GH internalisation we considered an
important role for multivesicular endosomes. Previously, we have
shown that GHR concentrates in flat clathrin-containing structures
that might act as sorting stations [26]. First, we localised cy3-GH
endocytosed via bothwild type GHR and GHR349 inHek293 cells. In
both cases the fluorescence was mainly present in small vesicles,
presumably endosomes (Fig. 2A). Next, we depleted cells for TrCP
and repeated the uptake experiment. While GH uptake via the wild
type receptor was strongly inhibited at the cell surface, GHR349-
bound cy3-GH accumulated in numerous vesicles, around the
nucleus, in peripheral vesicles and, strikingly, at the plasma
membrane. TrCP generally functions as the substrate-binding factor
in SCFTrCP. To proof that TrCP acts in the context of a SCF ubiquitin
ligase we expressed GHR in hamster ts41 cells. These cells contain a
temperature-sensitive mutation in the NEDD8 activation enzyme,
APP-BP1 and fail either to degrade substrates (e.g. p27 via the SCF
(skp2)), or endocytose GH via E3s with Cullin family members, due
to defective Neddylation [6,27]. Fig. 2B shows that cy3-GH is
endocytosed and degraded at the permissive temperature, but
strongly accumulates intracellularly at the non-permissive temper-
ature (39 °C). In the same experiment, Alexa488-labelled transferrin
entered the cells undisturbed (not shown). This shows that an intact
neddylation system is specifically required for both uptake of
cy3-GH, as we showed previously, via the wild type GHR [6] and
transport through endosomes of cy3-GH via the truncated GHR.
These data strongly suggest that GHR349 requires a fully functional
SCF(βTrCP) complex to pass the endosomes.
Previously, we showed that most wild type GHR resides at the
cell surface and little intracellular. As the uptake of GH via GHR349
is much faster than via the wild type GHR we measured their
location by treating the cells with proteinase K on ice. Fig. 2C
shows that almost no mature GHR349 was digestible by the
protease while most (>70%) of the wild type mature GHR
disappeared. Thus, most of the GHR349 is present inside the
cells, presumably in endosomes. In Fig. 2D we isolated the GHR349
from the cell surface after incubation with biotinylated GH on ice
from TrCP-depleted and control-treated cells. Quantification
showed a 3-fold increase of label at the cell surface if TrCP was
silenced. As expected, almost no precursor GHR was detectable.Taken together with the conclusion from Fig. 1B that GH uptake is
unaffected, we conclude that the truncated receptor recycles to the
cell surface in the absence of TrCP.
TrCP acts in GHR sorting at endosomes
The final step of the degradation of growth factor receptors, as best
exemplified by the EGFR, depends on translocation from the
limiting membrane of MVBs to internal vesicles. This is regarded a
definitive–irreversible–step that halts signaling and delivers the
receptors to Hops-mediated transfer into lysosomes [28,29]. As our
experiments show that TrCP is required for GH degradation via the
GHR349, the question was at which stage it acts. We used two
well-established traffic markers, transferrin (Tf) to mark the
recycling route (PM, early endosomes, recycling endosomes) and
the late endosome/lysosome marker, Lamp1. Fig. 3A shows little
co-localisation between cy3-GH and Alexa488-Tf after 30 min
incubation. However, if TrCP expression was silenced both labels
coincided (Fig. 3B). The degree of overlap between Tf and GH was
quantified using the Manders overlap coefficient (Fig. 3E). In most
cells at steady state the majority of the Tf receptors were inside
(~80%). As the total amount of Alexa-Tf present in the cells did not
change upon TrCP silencing, TrCP did not affect Tf uptake and
recycling quantitatively, but it did affect the intracellular distribu-
tion: both labels coincide, very likely in the so-called recycling
compartment, that contains tubulovesicular structures and
recycles EGF and Tf with slow kinetics [30,31]. As TrCP silencing
has no effect on EGFR trafficking (not shown) it is unlikely that
TrCP has a general role in MVB sorting.
If cy3-GH is taken up for 30 min followed by a 30-min chase, a
significant overlap occurred with the late-endosomal marker
Lamp1 (Fig. 3C). Quantification of overlap was difficult in many
endosomal vesicles in which cy3-GH was in the lumen, while
Lamp1 staining lined the vesicle (Fig. 3C, right panel). In case TrCP
was silenced the overlap was significantly smaller. Strikingly, a
typical difference is visible in many cells after siRNA treatment
compared to control siRNA (Fig. 3D). Even after 60 min of cy3-GH
uptake little co-localisation with Lamp1 is apparent. Thus, TrCP
gene silencing blocks entry into late endosomes. These results
strengthen our conclusion that TrCP is required to promote GHR
into the degradative route, beyond the MVBs.
Previously, we have shown that TrCP is required for GHR
internalisation and binds to the UbEmotif (DDSWVEFIELDIDD) [6].
Thus,mutation of thismotif prevents the TrCP-GHR interaction and
should generate the same phenotypes as TrCP silencing. Indeed,
Fig. 4 shows a strong co-localisation between Tf and GH in the cells
expressing the GHR349 F227Amutant. Notably, the label is mostly
in endosomal vesicles, rather than in the recycling compartment.
As for Lamp1 staining (Fig. 4B), all cells demonstrate the same
phenotype as in Fig. 3A. Thus, removal of TrCP aswell as destroying
its binding motif in the GHR diverts the GHR to the recycling
pathway.
The ESCRT connection
Signaling receptors can continue to transmit signals from
endosomal compartments and it is clear from many studies that
due to organelle-specific sets of signaling factors signals from
endosomes differ from signals generated at the plasma membrane
[28]. From a mechanistic point of view it is very important to
Fig. 4 –Mutation of the TrCP binding site diverts cy3-GH to the recycling pathway. A. GHR349(F327A) expressing Hek293 cells were
incubated with cy3-GH and Alexa488-Tf as for GHR349-expressing cells in Fig. 3A–B. In B the cells were incubated with cy3-GH and
then chased for 30 min without GH. After fixation the cells were treated with triton-X100 and incubated with anti-Lamp1 and
Alexa488-labelled anti-mouse IgG. The amount of co-labelling was determined according to Manders and expressed as a coefficient
of co-localisation (C). Data are representative of three independent experiments. Bar, 5 μm.
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intraluminal vesicles of MVBs is regarded beyond signaling stage.
Above, we have shown that SCFTrCP is a sorting factor that acts in an
early stage of sequestering. For the receptor tyrosine kinases that
depend on Cbl for their degradation, like EGFR, the Hrs-STAM
complex is involved in sorting toMVBs inmammalian cells [32,33].
Eliminating either of the two factors forces the EGFR into the
recyclingmode [34]. To investigate whether SCFTrCP also acts at the
MVB level for the GHR, we have silenced two ubiquitin binding
factors of the ESCRT machinery: Hrs as the presumed receptor for(c-Cbl-mediated) ubiquitinated cargo in the ESCRT-0 complex, and
Tsg101 as the UEV-domain containing receptor for Hrs (via PSAP)
and retroviral proteins via their late domains (PTAP, PPPY and/or
YPDL). Experiments with 125I-GH are most informative as they
measure quantitatively uptake, transport, and degradation. We
optimised the protocol for all three parameters and decided to use
a 60-min chase period following a 15-min label period. As neither
Hrs nor Tsg101 are involved in GHR internalisation, we used
Hek293 cells expressing wild type GHR rather than GHR349. Fig. 5
shows that 55% of the total 125I-GH radioactivity had exited the
Fig. 5 – Effect of Hrs, Tsg101 and TrCP silencing on 125I-GH
distribution and degradation. Wild type GHR expressing
Hek293 cells were treated with the indicated silencing
oligonucleotides for 3 days and then incubated for 15 min with
125I-GH. After a 60-min chase period the amounts of label at the
cell surface, at intracellular locations as well as the TCA-soluble
radioactivity in the culture medium were quantitated and
expressed as percentage of total radioactivity. All data in this
figure are representative of three independent experiments.
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and only 10% was present at the cell surface. If the cells were
treated with siRNAs for either Tsg101 or Hrs the amount of
degradation was inhibited to 10% and 20%, respectively. The most
striking difference between Hrs and Tsg101 silencing concerns
their ratios cell surface/intracellular: approximately 2:1 for Tsg101
and 1:2 for Hrs silencing. This difference was consistently present,
also if the chase time was either shortened or prolonged. As a
control for internalisation we used siRNA oligonucleotides to
silence TrCP: as expected the 125I-GH-GHR complex was mostly
kept at the plasma membrane (62%), while only 23% was
intracellular, and 15% was degraded. In all cases gene silencing
was better than 80% based on western blotting (not shown). We
conclude that both Tsg101 and Hrs are required for GH degradation,
and that in the absence of Tsg101 GH accumulates mainly at the cell
surface, while Hrs silencing causes a strong intracellular
accumulation.
To determine the effect of gene silencing more precisely, we
compared the localisation of cy3-GH and alexa488-Tf under
different conditions. To ascertain that the effects are generally
valid, we used human osteosarcoma (U2OS) cells expressing
exogenouswild type GHRs. A second advantage of the U2OS cells is
their extended endosomal system that facilitates analysis of
phenotypic differences. As for GHR349 in Hek293 cells (Fig. 3A),
in U2OS cells there is little co-localisation between cy3-GH and Tf
(Fig. 6A). Treatment with Hrs-specific siRNA caused a redistribu-
tion of both labels towards the perinuclear region, but did not
result in co-localisation of GH and Tf (Fig. 6B). Close examination
reveals a characteristic labelling pattern: cy3-GH is present in
enlarged vacuoles that are often capped with little structures
containing alexa488-Tf (Fig. 6B, right panel). If Tsg101 expressionwas silenced, the two labels show extensive co-localisation,
comparable to the distribution after TrCP silencing (Fig. 2A). In
addition, cy3-GH convincingly stained the plasma membrane.
Tsg101-silencing probably caused a slight increase in vesicular size
(Fig. 6C, right panel). As a control we silenced the cells for βTrCP;
Fig. 6D shows that in this case the cy3-GH label is almost
exclusively at the plasma membrane. The results of Fig. 6 confirm
the biochemical data from Fig. 5 that both Hrs and Tsg101
depletion specifically affect the cy3-GH transport. In addition, they
show that Hrs depletion does not prevent segregation of Tf and GH,
while Tgs101 depletion forces GH in the Tf-recycling pathway,
illustrated by clear cell surface labelling. Although Hrs depletion
affects endosomal functions, included GHR degradation, GH
sorting in MVB does not seem to require Hrs, as it has been
reported for sorting of the activated EGFR [34].
The EGFR can be considered the best-studied signalling
receptor. Although there are still uncertainties about how the
receptor is endocytosed, there is consensus about the route the
EGFR takes to lysosomes: after internalisation, EGFR is transported
via early endosomes and delivered toMVBwhere c-Cbl, STAM-Hrs,
and ESCRTI-III mediate the formation of intraluminal vesicles
[35–38], after which the receptor is degraded in the lysosomes.
Until now we have shown that the routing of the GHR requires the
ubiquitination factors (SCFTrCP) to enter the cell as well as to
progress to lysosomes via the MVBs, and ESCRT factors. Therefore,
we asked whether the two receptors indeed take the same route to
lysosomes. As seen in Fig. 7, Alexa488-EGF and cy3-GH show a
complete overlap in cells that express both the GHR and the EGFR.
We conclude that the two prototype receptors, representing the
cytokine receptor and the RTK families, use the same vesicular
structures on their way to lysosomes, despite the use of different
sorting factors.Discussion
In this study we have analysed the endosomal sorting of the GHR.
As SCFTrCP is needed for GHR internalisation, we used a GHR,
truncated at Ser349 that can enter cells via a di-leucine motif
(DxxxLLS349). This enabled TrCP gene silencing experiments to
study the sorting mechanism at the endosomal level. All
parameters tested for internalisation and degradation show that
GHR349 behaves similar to wild type GHR except that its
internalisation rate is higher, probably due to the high affinity
binding to AP2 [22,23]. In this study we add more parameters that
underscore the hypothesis that the truncated and wild type GHRs
use identical mechanisms to travel through the endosomal
system: The routing of GH taken by the two receptors is the
same, gene silencing of Hrs and Tsg101 affect the two receptors
similarly, and, importantly, the requirement of both TrCP activity
and SCFTrCP neddylation at the cell surface as well as intracellularly.
Nevertheless, it cannot completely be excluded that the truncated
tail segment plays some role in sorting at the endosomes.
Our analysis revealed that the ubiquitin ligase SCFTrCP is
required for routing the GHR349 and its ligand to the lysosomes
via MVBs. Although all details of the sorting process are not yet
clear, our data show that TrCP acts via the UbE motif. It became
apparent that deactivation of ESCRT-I by silencing Tsg101
generated the same phenotype as mutation of the TrCP binding
motif UbE. In both cases the GHR was forced into a recycling route,
Fig. 6 – Hrs and Tsg101 play different roles in cy3-GH trafficking. Wild type GHR expressing U2OS cells were treated with the
indicated silencing oligonucleotides for 3 days and then incubated for 30 min with cy3-GH. The label was replaced by Alexa488-Tf
and the incubation was continued for 30 min. The cells were fixed in p-formaldehyde and the labels were visualised by confocal
microscopy. The pictures are representative for 3 independent experiments. At the right side phenotypic parts of cells are enlarged
to demonstrate the differences between the silencing effects of Hrs and Tsg101, respectively. Bar, 5 μm.
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been proposed for HFE hemochromatosis that requires Tsg101 and
K63 ubiquitination by the K5 E3 for lysosomal degradation [39].
However, it differs fromthe sortingofRTK familymembers. For these
receptors c-Cbl acts in a ligand-induced fashion to ubiquitinate the
receptor tails, which then serve as binding partners for the ubiquitin
binding domains of ESCRT-0, presumably the ubiquitin-interactingmotif (UIM) of Hrs [1,40–42]. In the absence of ESCRT-0 the
recruitment of ESCRT-I is inhibited [37]. In accordance, Wollert and
Hurley infer from their in vitro data that ESCRT-0 is themain driving
force for cargo clustering. This is probably true for all ubiquitinated
cargo. Previously, we have shown that internalisation of a GHRwith
all lysine residues removed from the cytosolic tail (GHR-K−) still
requires an active ubiquitination system [21]. We have performed
Fig. 7 – Alexa488-EGF and cy3-GH travel through similar endocytic compartments. U2OS cells expressing both GHR and EFGR were
incubated with cy3-GH and Alexa488-EGF for 30 min and fixed with p-formaldehyde. The cells were visualised by confocal
immunofluorescence microscopy. The pictures are representative of three independent experiments. Bar, 5 μm.
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anything aberrant from the data presented above (not shown).
Magadan and co-workers have shown that SCFTrCP can utilise serine
and threonine residues as ubiquitin targets [43]. In our experiments
with lysine-less receptor tails we have never observed any increase
in apparentmolecularweight, nor didwe observe a positive reaction
with anti-ubiquitin onwesternblots. Thus, these results confirm that
neither the wild type GHR nor the GHR349 are obligatory targets for
TrCP. This might explain why we find the ubiquitin ligase (SCFTrCP)
acting at the level of Tsg101/ESCRT-I rather than Hrs/ESCRT-0. It is
still unclear what substrate is targeted for ubiquitination (as it is for
manyE3s). It is likely that E3 enzymeactivity is needed to advanceGH
into the lysosomes as we probed the effect of Cullin1 neddylation in
rat ts41 cells [27]: at non-permissive temperature the cy3-GH
remained in the Tf-recycling pathway.
Although gene silencing of Hrs did not inhibit the sorting
process between Tf and GH it affected the appearance of the Tf
route (Fig. 6B). Indeed, Yan et al. showed that rapid recycling of Tf
requires a Hrs-containing complex that also includes actinin, BERP,
andmyosin V. Disruption of this complex caused rerouting of Tf via
a slower recycling route that involves recycling tubules [30,31].
Apparently, cy3-GH is sorted from Tf but cannot continue its
journey to the lysosomes due to a general trafficking defect caused
by the depletion of Hrs (Figs. 5 and 6B). The literature is somewhat
unclear at this point: Razi et al. show that depletion of Tsg101
strongly inhibits EGF degradation as well as MVB formation, while
Hrs depletion inhibits EGF degradation only slightly [44]. Raiborg
et al. show that depletion of both Tsg101 and Hrs caused enhanced
recycling of endocytosed EGFR, while depletion of both Vps22
(EAP30, ESCRT-II) and Vps24 (CHP3, ESCRT-III) did not [34]. Our
data are in agreement with both observations if one assumes that
both Hrs and Tsg101 have a general role in MVB cargo sorting.
An important difference between the RTK family receptors and the
GHR is that the former recycle between the cell surface and the MVB
until they become activated. Mostly c-Cbl, but also Nedd4 and a few
other E3s, are recruited tomotifs containing aphosphorylated tyrosine
residue. Once complexed with the receptors they ubiquitinate the
receptor tails that then serve as recognition markers for the MVB
sorting machinery, most likely for ESCRT-0, reviewed in [1]. If c-Cbl-
dependent ubiquitination is prevented in Met or EGF receptors, cells
become transforming and tumorigenic due to the sustained activationof downstream signalling pathways [45,46]. Multiplemono and Lys63
polyubiquitination are required for degradation of RTKs [47,48]. It is
likely that cargo selection of the GHR at MVBs requires Lys63
ubiquitination as well. As SCFTrCP is generally involved in Lys48
polyubiquitination, further studies are needed to solve this question.
Is it expected that the SCFTrCP targets more substrates to the
lysosomes? In several cytokine receptor family members including
IFNAR1, PRLR and EpoR ligand-induced ubiquitination and proteolysis
occur via phosphorylation of specific serine residues within the
cytoplasmic domain [3,4]. In the case of IFNAR1 and the PRLR, receptor
phosphorylation within the β-TrCP-binding motif requires the
catalytic activity of the associated Jak kinase activity [49–51]. For the
PrlR, lysosomal delivery of the PrlRS349A mutant is decreased
compared to wild type. In this case βTrCP might act through Lys63
polyubiquitination, as expression ofmutant ubiquitin, either defective
in polymerisation or in K63 chain formation inhibited degradation.
Whether the decreased PrlR degradation results from impaired
lysosomal degradation or from impaired internalisation remains
unclear. The cells expressing the ubiquitin mutant do show a
decreased sorting of the PrlR to the acidic compartments, but also
show a decline in AP2 interaction and initiation of internalisation [52].
Very likely, the levels of most cytokine receptors are regulated
by multiple mechanisms partly controlled by their cognate ligands
and by other factors including stressors [6,53]. This study shows
for the first time that ubiquitination via SCFTrCP is required both at
the cell surface and in the MVBs to degrade a cytokine receptor. As
the downstream machinery in both locations (clathrin- versus
ESCRT-mediated) differs, the factors linking the ubiquitination-
based selection machinery to the two general systems will
certainly differ as well. A common feature is that SCFTrCP can act
ligand-independently as GHR349 degradation is blocked both in
the presence and absence of GH after TrCP silencing [23].Acknowledgments
We thank all other members of the GHR group for suggestions and
helpful discussions, and Erinke van Grinsven for her contribution
to the discussion. The investigations were in part supported by the
European Network of Excellence “Rubicon” (LSHG-CT-2005-
018683).
1081E X P E R I M E N T A L C E L L R E S E A R C H 3 1 7 ( 2 0 1 1 ) 1 0 7 1 – 1 0 8 2R E F E R E N C E S
[1] F. Acconcia, S. Sigismund, S. Polo, Ubiquitin in trafficking: the
network at work, Exp. Cell Res. 315 (2009) 1610–1618.
[2] M.I. Irandoust, L.H. Aarts, O. Roovers, J. Gits, S.J. Erkeland,
I.P. Touw, Suppressor of cytokine signaling 3 controls
lysosomal routing of G-CSF receptor, EMBO J. 26 (2007)
1782–1793.
[3] K.G.S. Kumar, J.J. Krolewski, S.Y. Fuchs, Phosphorylation and
specific ubiquitin acceptor are required for ubiquitination and
degradation of the IFNAR1 subunit of type I Interferon receptor,
J. Biol. Chem. 279 (2004) 46614–46620.
[4] Y. Li, K.G. Suresh Kumar, W. Tang, V.S. Spiegelman, S.Y. Fuchs,
Negative regulation of prolactin receptor stability and signaling
mediated by SCF{beta}-TrCP E3 ubiquitin ligase, Mol. Cell. Biol. 24
(2004) 4038–4048.
[5] L.Meyer, B. Deau, H. Forejtnikova, D. Dumenil, F.Margottin-Goguet,
C. Lacombe, P. Mayeux, F. Verdier, Beta-Trcp mediates
ubiquitination and degradation of the erythropoietin receptor and
controls cell proliferation, Blood 109 (2007) 5215–5222.
[6] P. van Kerkhof, J. Putters, G.J. Strous, The Ubiquitin lgase SCF
(betaTrCP) regulates the degradation of the growth hormone
receptor, J. Biol. Chem. 282 (2007) 20475–20483.
[7] D.J. Katzmann, G. Odorizzi, S.D. Emr, Receptor downregulation
and multivesicular-body sorting, Nat. Rev. Mol. Cell Biol. 3 (2002)
893–905.
[8] R.L. Williams, S. Urbe, The emerging shape of the ESCRT
machinery, Nat. Rev. Mol. Cell Biol. 8 (2007) 355–368.
[9] J. Gruenberg, H. Stenmark, The biogenesis of multivesicular
endosomes, Nat. Rev. Mol. Cell Biol. 5 (2004) 317–323.
[10] J.H. Hurley, S.D. Emr, The ESCRT complexes: structure and
mechanism of a membrane-trafficking network, Annu. Rev.
Biophys. Biomol. Struct. 35 (2006) 277–298.
[11] W.I. Sundquist, H.L. Schubert, B.N. Kelly, G.C. Hill, J.M. Holton, C.P.
Hill, Ubiquitin recognition by the human TSG101 protein, Mol.
Cell 13 (2004) 783–789.
[12] H. Teo, D.J. Gill, J. Sun, O. Perisic, D.B. Veprintsev, Y. Vallis, S.D.
Emr, R.L. Williams, ESCRT-I Core and ESCRT-II GLUE domain
structures reveal role for GLUE in linking to ESCRT-I and
membranes, Cell 125 (2006) 99–111.
[13] T. Wollert, J.H. Hurley, Molecular mechanism of multivesicular
body biogenesis by ESCRT complexes, Nature 464 (2010)
864–869.
[14] K. Umebayashi, H. Stenmark, T. Yoshimori, Ubc4/5 and c-Cbl
continue to ubiquitinate EGF receptor after internalization to
facilitate polyubiquitination and degradation, Mol. Biol. Cell 19
(2008) 3454–3462.
[15] N. Belgareh-Touze, S. Leon, Z. Erpapazoglou, M. Stawiecka-Mirota,
D. Urban-Grimal, R. Haguenauer-Tsapis, Versatile role of the yeast
ubiquitin ligase Rsp5p in intracellular trafficking, Biochem. Soc.
Trans. 36 (2008) 791–796.
[16] I. Amit, L. Yakir, M. Katz, Y. Zwang, M.D. Marmor, A. Citri, K.
Shtiegman, I. Alroy, S. Tuvia, Y. Reiss, E. Roubini, M. Cohen, R.
Wides, E. Bacharach, U. Schubert, Y. Yarden, Tal, a Tsg101-specific
E3 ubiquitin ligase, regulates receptor endocytosis and retrovirus
budding, Genes Dev. 18 (2004) 1737–1752.
[17] S. Polo, S. Sigismund, M. Faretta, M. Guidi, M.R. Capua, G. Bossi, H.
Chen, P. De Camilli, P.P. Di Fiore, A single motif responsible for
ubiquitin recognition and monoubiquitination in endocytic
proteins, Nature 416 (2002) 451–455.
[18] M. Kato, K. Miyazawa, N. Kitamura, A deubiquitinating enzyme
UBPY interacts with the Src homology 3 domain of Hrs-binding
protein via a novel binding motif PX(V/I)(D/N)RXXKP, J. Biol.
Chem. 275 (2000) 37481–37487.
[19] E. Mizuno, T. Iura, A. Mukai, T. Yoshimori, N. Kitamura, M.
Komada, Regulation of epidermal growth factor receptor
down-regulation by UBPY-mediated deubiquitination at
endosomes, Mol. Biol. Cell 16 (2005) 5163–5174.[20] P.E. Row, H. Liu, S. Hayes, R. Welchman, P. Charalabous, K.
Hofmann, M.J. Clague, C.M. Sanderson, S. Urbe, The MIT domain of
UBPY constitutes a CHMP binding and endosomal localization
signal required for efficient epidermal growth factor receptor
degradation, J. Biol. Chem. 282 (2007) 30929–30937.
[21] R. Govers, T. ten Broeke, P. van Kerkhof, A.L. Schwartz, G.J. Strous,
Identification of a novel ubiquitin conjugation motif, required for
ligand-induced internalization of the growth hormone receptor,
EMBO J. 18 (1999) 28–36.
[22] R. Govers, P. van Kerkhof, A.L. Schwartz, G.J. Strous,
Di-leucine-mediated internalization of ligand by a truncated growth
hormone receptor is independent of the ubiquitin conjugation
system, J. Biol. Chem. 273 (1998) 16426–16433.
[23] P. van Kerkhof, C.M. Alves dos Santos, M. Sachse, J. Klumperman,
G. Bu, G.J. Strous, Proteasome inhibitors block a late step in
lysosomal transport of selected membrane but not soluble
proteins, Mol. Biol. Cell 12 (2001) 2556–2566.
[24] G.J. Strous, P. van Kerkhof, R. Govers, A. Ciechanover, A.L.
Schwartz, The ubiquitin conjugation system is required for
ligand-induced endocytosis and degradation of the growth
hormone receptor, EMBO J. 15 (1996) 3806–3812.
[25] S. Bolte, F.P. Cordelieres, A guided tour into subcellular
colocalization analysis in light microscopy, J. Microsc. 224 (2006)
213–232.
[26] M. Sachse, S. Urbe, V. Oorschot, G.J. Strous, J. Klumperman,
Bilayered clathrin coats on endosomal vacuoles are involved in
protein sorting toward lysosomes, Mol. Biol. Cell 13 (2002)
1313–1328.
[27] M. Ohh, W.Y. Kim, J.J. Moslehi, Y. Chen, V. Chau, M.A. Read, W.G.
Kaelin Jr., An intact NEDD8 pathway is required for
Cullin-dependent ubiquitylation in mammalian cells, EMBO Rep.
3 (2002) 177–182.
[28] J.E. Murphy, B.E. Padilla, B. Hasdemir, G.S. Cottrell, N.W. Bunnett,
Endosomes: a legitimate platform for the signaling train, Proc.
Natl Acad. Sci. USA 106 (2009) 17615–17622.
[29] D.P. Nickerson, C.L. Brett, A.J. Merz, Vps-C complexes:
gatekeepers of endolysosomal traffic, Curr. Opin. Cell Biol. 21
(2009) 543–551.
[30] E.M. van Dam, T. ten Broeke, K. Jansen, P. Spijkers, W. Stoorvogel,
Endocytosed transferrin receptors recycle via distinct dynamin
and phosphatidylinositol 3-kinase-dependent pathways, J. Biol.
Chem. 277 (2002) 48876–48883.
[31] A. Sorkin, S. Krolenko, N. Kudrjavtceva, J. Lazebnik, L. Teslenko, A.M.
Soderquist, N. Nikolsky, Recycling of epidermal growth
factor-receptor complexes in A431 cells: identification of dual
pathways, J. Cell Biol. 112 (1991) 55–63.
[32] M. Komada, N. Kitamura, The Hrs/STAM complex in the
downregulation of receptor tyrosine kinases, J. Biochem. 137
(2005) 1–8.
[33] L. Duan, Y. Miura, M. Dimri, B. Majumder, I.L. Dodge, A. Lakku
Reddi, A.K. Ghosh, N. Fernandes, P. Zhou, K. Mullane-Robinson, N.
Rao, S. Donoghue, R.A. Rogers, D. Bowtell, M. Naramura, H. Gu, V.
Band, H. Band, Cbl-mediated ubiquitinylation is required for
lysosomal sorting of EGF receptor but is dispensable for
endocytosis, J. Biol. Chem. 278 (2003) 28950–28960.
[34] C. Raiborg, L. Malerod, N.M. Pedersen, H. Stenmark, Differential
functions of Hrs and ESCRT proteins in endocytic membrane
trafficking, Exp. Cell Res. 314 (2008) 801–813.
[35] M. Babst, D.J. Katzmann, W.B. Snyder, B. Wendland, S.D. Emr,
Endosome-associated complex, ESCRT-II, recruits transport
machinery for protein sorting at the multivesicular body, Dev Cell
3 (2002) 283–289.
[36] D.J. Katzmann, M. Babst, S.D. Emr, Ubiquitin-dependent sorting
into the multivesicular body pathway requires the function of a
conserved endosomal protein sorting complex, ESCRT-I, Cell 106
(2001) 145–155.
[37] K.G. Bache, A. Brech, A. Mehlum, H. Stenmark, Hrs regulates
multivesicular body formation via ESCRT recruitment to endosomes,
J. Cell Biol. 162 (2003) 435–442.
1082 E X P E R I M E N T A L C E L L R E S E A R C H 3 1 7 ( 2 0 1 1 ) 1 0 7 1 – 1 0 8 2[38] K.G. Bache, C. Raiborg, A. Mehlum, H. Stenmark, STAM and Hrs are
subunits of a multivalent ubiquitin-binding complex on early
endosomes, J. Biol. Chem. 278 (2003) 12513–12521.
[39] D.A. Rhodes, L.H. Boyle, J.M. Boname, P.J. Lehner, J. Trowsdale,
Ubiquitination of lysine-331 by Kaposi's sarcoma-associated
herpesvirus protein K5 targets HFE for lysosomal degradation,
Proc. Natl Acad. Sci. USA 107 (2010) 16240–16245.
[40] P.S. Bilodeau, J.L. Urbanowski, S.C. Winistorfer, R.C. Piper, The
Vps27p Hse1p complex binds ubiquitin and mediates endosomal
protein sorting, Nat. Cell Biol. 4 (2002) 534–539.
[41] C. Raiborg, K.G. Bache, D.J. Gillooly, I.H. Madshus, E. Stang, H.
Stenmark, Hrs sorts ubiquitinated proteins into clathrin-coated
microdomains of early endosomes, Nat. Cell Biol. 4 (2002)
394–398.
[42] S. Hirano, M. Kawasaki, H. Ura, R. Kato, C. Raiborg, H. Stenmark, S.
Wakatsuki, Double-sided ubiquitin binding of Hrs-UIM in endosomal
protein sorting, Nat. Struct. Mol. Biol. 13 (2006) 272–277.
[43] J.G. Magadan, F.J. Perez-Victoria, R. Sougrat, Y. Ye, K. Strebel, J.S.
Bonifacino, Multilayered mechanism of CD4 downregulation by
HIV-1 Vpu involving distinct ER retention and ERAD targeting
steps, PLoS Pathog. 6 (2010) e1000869.
[44] M. Razi, C.E. Futter, Distinct roles for Tsg101 and Hrs in
multivesicular body formation and inward vesiculation, Mol. Biol.
Cell 17 (2006) 3469–3483.
[45] P. Peschard, T.M. Fournier, L. Lamorte, M.A. Naujokas, H. Band, W.Y.
Langdon, M. Park, Mutation of the c-Cbl TKB domain binding site on
the Met receptor tyrosine kinase converts it into a transforming
protein, Mol. Cell 8 (2001) 995–1004.
[46] J.V. Abella, P. Peschard, M.A. Naujokas, T. Lin, C. Saucier, S. Urbe, M.
Park, Met/Hepatocyte growth factor receptor ubiquitination
suppresses transformation and is required for Hrs phosphorylation,
Mol. Cell. Biol. 25 (2005) 9632–9645.[47] L.M. Duncan, S. Piper, R.B. Dodd, M.K. Saville, C.M. Sanderson, J.P.
Luzio, P.J. Lehner, Lysine-63-linked ubiquitination is required for
endolysosomal degradation of class I molecules, EMBO J. 25
(2006) 1635–1645.
[48] T. Geetha, J. Jiang, M.W. Wooten, Lysine 63 polyubiquitination of
the nerve growth factor receptor TrkA directs internalization and
signaling, Mol. Cell 20 (2005) 301–312.
[49] Z. Marijanovic, J. Ragimbeau, K.G. Kumar, S.Y. Fuchs, S. Pellegrini,
TYK2 activity promotes ligand-induced IFNAR1 proteolysis,
Biochem. J. 397 (2006) 31–38.
[50] G. Swaminathan, B. Varghese, C. Thangavel, C.J. Carbone, A.
Plotnikov, K.G. Kumar, E.M. Jablonski, C.V. Clevenger, V. Goffin, L.
Deng, S.J. Frank, S.Y. Fuchs, Prolactin stimulates ubiquitination,
initial internalization, and degradation of its receptor via catalytic
activation of Janus kinase 2, J. Endocrinol. 196 (2008) R1–R7.
[51] P. Walrafen, F. Verdier, Z. Kadri, S. Chretien, C. Lacombe, P.
Mayeux, Both proteasomes and lysosomes degrade the activated
erythropoietin receptor, Blood 105 (2005) 600–608.
[52] B. Varghese, H. Barriere, C.J. Carbone, A. Banerjee, G.
Swaminathan, A. Plotnikov, P. Xu, J. Peng, V. Goffin, G.L. Lukacs,
S.Y. Fuchs, Polyubiquitination of prolactin receptor stimulates
its internalization, postinternalization sorting, and degradation
via the lysosomal pathway, Mol. Cell. Biol. 28 (2008)
5275–5287.
[53] S. Bhattacharya, W.C. HuangFu, J. Liu, S. Veeranki, D.P. Baker, C.
Koumenis, J.A. Diehl, S.Y. Fuchs, Inducible priming phosphorylation
promotes ligand-independent degradation of the IFNAR1 chain
of type I interferon receptor, J. Biol. Chem. 285 (2010)
2318–2325.
[54] J.S. Bonifacino, L.M. Traub, Signals for sorting of transmembrane
proteins to endosomes and lysosomes, Annu. Rev. Biochem. 72
(2003) 395–447.
